Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Want To Avoid A Refuse-To-File? Submit ANDA In English, FDA Says

Executive Summary

Generic applications continue to be tripped up by failing to adhere to other well-known standards such as paying user fees, US agency says.

You may also be interested in...



US FDA Begins Building Pharma Industry Activity Prediction Tool

Algorithms are intended to help predict incoming workload, which will be used to help set user fees.

New US FDA Generics Director Praises Industry, Encourages Partnerships

Refuse-to-receive rates for ANDAs are down, suggesting sponsors better understand the standards for quality applications, Office of Generic Drugs Director Sally Choe says in first speech to industry.

ANDA Sponsors Need To 'Slow Down' And Focus On Quality, US FDA Generics Director Says

Kathleen Uhl says applicants can avoid RTRs by conducting quality checks before submission, but sponsors may have difficulty changing their approach because of how fundamental application speed is to their business model.

Related Content

Topics

UsernamePublicRestriction

Register

PS122139

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel